-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, EnYoXzTM/1rbI1zEZYLx6c3I8oWHzgh4yAZjF+FuIde5oLgfkOEQPSZJYoiP/rKK +WzBGyFdSpv/AMA3sjW4MA== 0000725058-08-000017.txt : 20080509 0000725058-08-000017.hdr.sgml : 20080509 20080509155928 ACCESSION NUMBER: 0000725058-08-000017 CONFORMED SUBMISSION TYPE: 15-12G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20080509 DATE AS OF CHANGE: 20080509 EFFECTIVENESS DATE: 20080509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CYTOGEN CORP CENTRAL INDEX KEY: 0000725058 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 222322400 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12G SEC ACT: 1934 Act SEC FILE NUMBER: 000-14879 FILM NUMBER: 08818415 BUSINESS ADDRESS: STREET 1: 650 COLLEGE RD EAST STE 3100 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 6099878200 MAIL ADDRESS: STREET 1: 650 COLLEGE RD EAST STE 3100 CITY: PRINCETON STATE: NJ ZIP: 08540 15-12G 1 form_15.htm FORM 15 form_15.htm
 
 OMB APPROVAL
OMB Number:          3235-0167
Expires:     November 30, 2010
Estimated average burden
hours per response . . . . . 1.50
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number: 000-14879

Cytogen Corporation 
(Exact name of registrant as specified in its charter)


650 College Road East, Suite 3100, Princeton, New Jersey 08540, (609) 750-8200  
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)


Common Stock, $0.01 par value 
(Title of each class of securities covered by this Form)


None 
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
 
 
Rule 12g-4(a)(1)(i)*
ý
  
Rule 12h-3(b)(1)(i)
ý
Rule 12g-4(a)(1)(ii)
£
  
Rule 12h-3(b)(1)(ii)
£
Rule 12g-4(a)(2)(i)
£
  
Rule 12h-3(b)(2)(i)
£
Rule 12g-4(a)(2)(ii)
£
  
Rule 12h-3(b)(2)(ii)
£
     
Rule 15d-6
£
                       
 
* The registrant is relying upon current Rule 12g-4(a)(1) to terminate the duty to file reports.

Approximate number of holders of record as of the certification or notice date:** One    

**All of the shares of Common Stock, $0.01 par value, of the registrant were purchased by EUSA Pharma, Inc., in connection with the merger of EUSA Pharma (USA), Inc, a wholly-owned subsidiary of EUSA Pharma, Inc., with and into the registrant, which became effective as of May 8, 2008.

Pursuant to the requirements of the Securities Exchange Act of 1934 Cytogen Corporation has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.**

Date:  May 9, 2008                                                                                          By:   /s/ KEVIN G. LOKAY        
                                                                Name:  Kevin G. Lokay
                    Title:    President and Chief Executive Officer
 

 
    Persons who respond to the collection of information contained
    in this form are not required to respond unless the form displays
SEC 2069 (12-04)                               a currently valid OMB control number.


 -----END PRIVACY-ENHANCED MESSAGE-----